An international perspective on preceding infections in Guillain-Barré Syndrome: the IGOS-1000 cohort
<strong>Background and objectives:</strong> Infections play a key role in the development of Guillain-Barré syndrome (GBS) and have been associated with specific clinical features and disease severity. The clinical variation of GBS across geographical regions has been suggested to be rel...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Academy of Neurology
2022
|
| _version_ | 1826310765984874496 |
|---|---|
| author | Leonhard, SE van der Eijk, AA Andersen, H Antonini, G Arends, S Attarian, S Barroso, FA Bateman, KJ Batstra, MR Benedetti, L van den Berg, B Van den Bergh, P Bürmann, J Busby, M Casasnovas, C Cornblath, DR Davidson, A Doets, AY van Doorn, PA Dornonville de la Cour, C Feasby, TE Fehmi, J Garcia-Sobrino, T Goldstein, JM Gorson, KC Granit, V Dm Hadden, R Harbo, T Hartung, H-P Hasan, I Holbech, JV Holt, JK Jahan, I Islam, Z Karafiath, S Katzberg, HD Kleyweg, RP Kolb, N Kuitwaard, K Kuwahara, M Kusunoki, S Luijten, LWG Kuwabara, S Lee Pan, E Lehmann, HC Maas, M Martín-Aguilar, L Miller, JA Mohammad, QD Monges, S Rinaldi, S |
| author_facet | Leonhard, SE van der Eijk, AA Andersen, H Antonini, G Arends, S Attarian, S Barroso, FA Bateman, KJ Batstra, MR Benedetti, L van den Berg, B Van den Bergh, P Bürmann, J Busby, M Casasnovas, C Cornblath, DR Davidson, A Doets, AY van Doorn, PA Dornonville de la Cour, C Feasby, TE Fehmi, J Garcia-Sobrino, T Goldstein, JM Gorson, KC Granit, V Dm Hadden, R Harbo, T Hartung, H-P Hasan, I Holbech, JV Holt, JK Jahan, I Islam, Z Karafiath, S Katzberg, HD Kleyweg, RP Kolb, N Kuitwaard, K Kuwahara, M Kusunoki, S Luijten, LWG Kuwabara, S Lee Pan, E Lehmann, HC Maas, M Martín-Aguilar, L Miller, JA Mohammad, QD Monges, S Rinaldi, S |
| author_sort | Leonhard, SE |
| collection | OXFORD |
| description | <strong>Background and objectives:</strong> Infections play a key role in the development of Guillain-Barré syndrome (GBS) and have been associated with specific clinical features and disease severity. The clinical variation of GBS across geographical regions has been suggested to be related to differences in the distribution of preceding infections, but this has not been studied on a large scale.
<br><strong>
Methods:</strong> We analysed the first 1000 patients included in the International GBS Outcome Study with available biosamples (n=768) for the presence of a recent infection with: Campylobacter jejuni, hepatitis E virus, Mycoplasma pneumoniae, cytomegalovirus, and Epstein-Barr virus.
<br><strong>
Results: </strong>Serological evidence of a recent infection with C. jejuni was found in 228 (30%), M. pneumoniae in 77 (10%), hepatitis E virus in 23 (3%), cytomegalovirus in 30 (4%) and Epstein-Barr virus in 7 (1%) patients. Evidence of more than one recent infection was found in 49 (6%) of these patients. Symptoms of antecedent infections were reported in 556 patients (72%), and this proportion did not significantly differ between those testing positive or negative for a recent infection. The proportions of infections were similar across continents. The sensorimotor variant and the demyelinating electrophysiological subtype were most frequent across all infection groups, although proportions were significantly higher in patients with a cytomegalovirus and significantly lower in those with a C. jejuni infection. C. jejuni–positive patients were more severely affected, indicated by a lower MRC sum score at nadir (P=0.004), and a longer time to regain the ability to walk independently (P=0.005). The pure motor variant and axonal electrophysiological subtype were more frequent in Asian compared to American or European C. jejuni-positive patients (P<0.001, resp. P= 0.001). Time to nadir was longer in the cytomegalovirus-positive patients (P=0.004).
<br><strong>
Conclusion: </strong>Across geographical regions, the distribution of infections was similar but the association between infection and clinical phenotype differed. A mismatch between symptom reporting and serological results and the high frequency of co-infections, demonstrate the importance of broad serological testing in identifying the most likely infectious trigger. The association between infections and outcome indicates their value for future prognostic models. |
| first_indexed | 2024-03-07T07:56:49Z |
| format | Journal article |
| id | oxford-uuid:f820ee14-2c59-4206-8c43-846df7e7e11c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:56:49Z |
| publishDate | 2022 |
| publisher | American Academy of Neurology |
| record_format | dspace |
| spelling | oxford-uuid:f820ee14-2c59-4206-8c43-846df7e7e11c2023-08-18T17:03:48ZAn international perspective on preceding infections in Guillain-Barré Syndrome: the IGOS-1000 cohortJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f820ee14-2c59-4206-8c43-846df7e7e11cEnglishSymplectic ElementsAmerican Academy of Neurology2022Leonhard, SEvan der Eijk, AAAndersen, HAntonini, GArends, SAttarian, SBarroso, FABateman, KJBatstra, MRBenedetti, Lvan den Berg, BVan den Bergh, PBürmann, JBusby, MCasasnovas, CCornblath, DRDavidson, ADoets, AYvan Doorn, PADornonville de la Cour, CFeasby, TEFehmi, JGarcia-Sobrino, TGoldstein, JMGorson, KCGranit, VDm Hadden, RHarbo, THartung, H-PHasan, IHolbech, JVHolt, JKJahan, IIslam, ZKarafiath, SKatzberg, HDKleyweg, RPKolb, NKuitwaard, KKuwahara, MKusunoki, SLuijten, LWGKuwabara, SLee Pan, ELehmann, HCMaas, MMartín-Aguilar, LMiller, JAMohammad, QDMonges, SRinaldi, S<strong>Background and objectives:</strong> Infections play a key role in the development of Guillain-Barré syndrome (GBS) and have been associated with specific clinical features and disease severity. The clinical variation of GBS across geographical regions has been suggested to be related to differences in the distribution of preceding infections, but this has not been studied on a large scale. <br><strong> Methods:</strong> We analysed the first 1000 patients included in the International GBS Outcome Study with available biosamples (n=768) for the presence of a recent infection with: Campylobacter jejuni, hepatitis E virus, Mycoplasma pneumoniae, cytomegalovirus, and Epstein-Barr virus. <br><strong> Results: </strong>Serological evidence of a recent infection with C. jejuni was found in 228 (30%), M. pneumoniae in 77 (10%), hepatitis E virus in 23 (3%), cytomegalovirus in 30 (4%) and Epstein-Barr virus in 7 (1%) patients. Evidence of more than one recent infection was found in 49 (6%) of these patients. Symptoms of antecedent infections were reported in 556 patients (72%), and this proportion did not significantly differ between those testing positive or negative for a recent infection. The proportions of infections were similar across continents. The sensorimotor variant and the demyelinating electrophysiological subtype were most frequent across all infection groups, although proportions were significantly higher in patients with a cytomegalovirus and significantly lower in those with a C. jejuni infection. C. jejuni–positive patients were more severely affected, indicated by a lower MRC sum score at nadir (P=0.004), and a longer time to regain the ability to walk independently (P=0.005). The pure motor variant and axonal electrophysiological subtype were more frequent in Asian compared to American or European C. jejuni-positive patients (P<0.001, resp. P= 0.001). Time to nadir was longer in the cytomegalovirus-positive patients (P=0.004). <br><strong> Conclusion: </strong>Across geographical regions, the distribution of infections was similar but the association between infection and clinical phenotype differed. A mismatch between symptom reporting and serological results and the high frequency of co-infections, demonstrate the importance of broad serological testing in identifying the most likely infectious trigger. The association between infections and outcome indicates their value for future prognostic models. |
| spellingShingle | Leonhard, SE van der Eijk, AA Andersen, H Antonini, G Arends, S Attarian, S Barroso, FA Bateman, KJ Batstra, MR Benedetti, L van den Berg, B Van den Bergh, P Bürmann, J Busby, M Casasnovas, C Cornblath, DR Davidson, A Doets, AY van Doorn, PA Dornonville de la Cour, C Feasby, TE Fehmi, J Garcia-Sobrino, T Goldstein, JM Gorson, KC Granit, V Dm Hadden, R Harbo, T Hartung, H-P Hasan, I Holbech, JV Holt, JK Jahan, I Islam, Z Karafiath, S Katzberg, HD Kleyweg, RP Kolb, N Kuitwaard, K Kuwahara, M Kusunoki, S Luijten, LWG Kuwabara, S Lee Pan, E Lehmann, HC Maas, M Martín-Aguilar, L Miller, JA Mohammad, QD Monges, S Rinaldi, S An international perspective on preceding infections in Guillain-Barré Syndrome: the IGOS-1000 cohort |
| title | An international perspective on preceding infections in Guillain-Barré Syndrome: the IGOS-1000 cohort |
| title_full | An international perspective on preceding infections in Guillain-Barré Syndrome: the IGOS-1000 cohort |
| title_fullStr | An international perspective on preceding infections in Guillain-Barré Syndrome: the IGOS-1000 cohort |
| title_full_unstemmed | An international perspective on preceding infections in Guillain-Barré Syndrome: the IGOS-1000 cohort |
| title_short | An international perspective on preceding infections in Guillain-Barré Syndrome: the IGOS-1000 cohort |
| title_sort | international perspective on preceding infections in guillain barre syndrome the igos 1000 cohort |
| work_keys_str_mv | AT leonhardse aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT vandereijkaa aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT andersenh aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT antoninig aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT arendss aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT attarians aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT barrosofa aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT batemankj aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT batstramr aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT benedettil aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT vandenbergb aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT vandenberghp aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT burmannj aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT busbym aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT casasnovasc aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT cornblathdr aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT davidsona aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT doetsay aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT vandoornpa aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT dornonvilledelacourc aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT feasbyte aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT fehmij aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT garciasobrinot aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT goldsteinjm aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT gorsonkc aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT granitv aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT dmhaddenr aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT harbot aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT hartunghp aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT hasani aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT holbechjv aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT holtjk aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT jahani aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT islamz aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT karafiaths aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT katzberghd aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT kleywegrp aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT kolbn aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT kuitwaardk aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT kuwaharam aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT kusunokis aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT luijtenlwg aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT kuwabaras aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT leepane aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT lehmannhc aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT maasm aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT martinaguilarl aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT millerja aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT mohammadqd aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT mongess aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT rinaldis aninternationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT leonhardse internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT vandereijkaa internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT andersenh internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT antoninig internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT arendss internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT attarians internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT barrosofa internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT batemankj internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT batstramr internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT benedettil internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT vandenbergb internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT vandenberghp internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT burmannj internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT busbym internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT casasnovasc internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT cornblathdr internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT davidsona internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT doetsay internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT vandoornpa internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT dornonvilledelacourc internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT feasbyte internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT fehmij internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT garciasobrinot internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT goldsteinjm internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT gorsonkc internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT granitv internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT dmhaddenr internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT harbot internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT hartunghp internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT hasani internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT holbechjv internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT holtjk internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT jahani internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT islamz internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT karafiaths internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT katzberghd internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT kleywegrp internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT kolbn internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT kuitwaardk internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT kuwaharam internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT kusunokis internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT luijtenlwg internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT kuwabaras internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT leepane internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT lehmannhc internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT maasm internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT martinaguilarl internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT millerja internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT mohammadqd internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT mongess internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort AT rinaldis internationalperspectiveonprecedinginfectionsinguillainbarresyndrometheigos1000cohort |